Covalon Technologies Ltd. (V:COV)
Business Focus: Biotechnology & Medical Research (NEC)
Mar 07, 2024 07:00 am ET
Covalon Announces Voting Results from Fiscal 2023 Annual Meeting of Shareholders
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders (“AGM”) held March 6, 2024.
Feb 28, 2024 07:00 am ET
Covalon Announces First Quarter Fiscal 2024 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2024 first quarter results for the period ended December 31, 2023.
Feb 28, 2024 07:00 am ET
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 6, 2024
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting of shareholders of the Company will be held on Wednesday, March 6, 2024 at 2:00pm Eastern Time in a virtual-only format where shareholders may attend and participate in the meeting via live webcast. The meeting will include a presentation from Covalon’s recently appointed CEO, Brent Ashton, with a Question and Answer session to follow.
Jan 26, 2024 07:10 am ET
Covalon Announces Management Changes
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the following management changes.
Jan 26, 2024 07:00 am ET
Covalon Announces Fourth Quarter and Year End Results for Fiscal 2023
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2023 fourth quarter and year end results for the period ended September 30, 2023.
Jan 04, 2024 07:00 am ET
Covalon Technologies Ltd. Announces the Appointment of Experienced MedTech Executive Mr. Brent Ashton as New CEO
Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that its Board of Directors (the “Board”) has appointed Mr. Brent Ashton to serve as Chief Executive Officer and a director of the Company, effective immediately.
Nov 15, 2023 10:00 am ET
Covalon’s VALGuard Gains Prestigious Recognition in the British Journal of Nursing
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today proudly announced the publication of an article in the British Journal of Nursing (BJN), titled “Guarding the Central Venous Access Device: A New Solution for an Old Problem”, authored by Darcy Doellman, MSN, RN, VA‐BC, a leading expert in pediatric vascular access.1 The article sheds light on innovative practices to strengthen infection prevention bundles used within vascular access by featuring VALGuard – a novel, transparent line guard that protects ce
Oct 20, 2023 07:00 am ET
Covalon Announces Issuance of Deferred Share Units
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of an aggregate of 295,000 deferred stock units (the "DSUs") to certain of its directors and officers. All DSUs were granted pursuant to the Company's omnibus long-term incentive plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.
Oct 13, 2023 07:00 am ET
Covalon Presents Innovative Solutions Used in Top Hospitals at the Association for Vascular Access (AVA) Annual Scientific Meeting in Portland, OR
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), a leader in advanced medical technologies, today announced its participation in the Association for Vascular Access (AVA) Annual Scientific Meeting Conference and Exhibit, to be held in Portland, Oregon from Saturday, October 14 to Monday, October 16, 2023. Visitors to booth 715 will have the opportunity to explore first-hand Covalon’s innovative vascular access and infection prevention solutions and learn more as to why top hospitals are choosing Covalon for their patients.
Oct 11, 2023 01:00 pm ET
Covalon to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), a leader in advanced medical technologies, today announced its participation in the American Nurses Credentialing Center (ANCC) Magnet Conference. Scheduled from Thursday, October 12 to Saturday, October 14, 2023, in Chicago, this conference is the largest conference for nurse professionals. All attendees are invited to booth 1835 at the McCormick Place Convention Center, where they can experience first-hand, innovative compassionate care solutions designed to elevate patient care standards and nursing excellence
Sep 26, 2023 07:00 am ET
Covalon Announces Leadership Changes
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that its Board of Directors (the “Board”) has appointed Amir Boloor, Chair of the Company’s Board, as Interim Chief Executive Officer (“CEO”), effective immediately following the departure of Brian Pedlar. The Board has commenced a search for a permanent CEO.
Sep 25, 2023 10:00 am ET
Life with a Central Line [WEBINAR]: Key Considerations from the Patient’s Perspective
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), a leader in advanced medical technologies, proudly announces the opening of registration for a unique, patient-led webinar. The event, scheduled for Wednesday, September 27, 2023, from 1-2 PM EST, is designed to provide attendees with a profound look into the patient’s world – living with central vascular access devices.
Sep 19, 2023 07:30 am ET
Covalon Showcases Compassionate Pediatric Care Solutions at 47th APHON Conference
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the 47th annual Association of Pediatric Hematology/Oncology Nurses (“APHON”) Conference and Exhibit, to be held in Cleveland, Ohio from Thursday, September 21 to Saturday, September 23, 2023. Covalon invites all attendees to booth 425 at the Huntington Convention Center, where they can explore our compassionate infection prevention solutions tailor made for pediatric patients.
Aug 16, 2023 07:00 am ET
Covalon Announces Third Quarter Fiscal 2023 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2023 results.
Aug 14, 2023 07:00 am ET
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2023 Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2023 financial results on Wednesday, August 16, 2023, before markets open. A conference call and webcast to discuss the financial results will be held on Wednesday, August 16, 2023, at 9:00am ET.
Jul 18, 2023 07:30 am ET
Premier Medical Journal Spotlights Covalon’s VALGUARD: A Novel Solution to Long-Standing Problem of Protecting Vascular Access Sites
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the publication of an article in the Journal of the Association for Vascular Access (JAVA), titled “Guarding the Central Venous Access Device: A New Solution for an Old Problem”, authored by Darcy Doellman, MSN, RN, VA-BC, a leading expert in pediatric vascular access. Recently retired from the top-ranked US Children’s Hospital, Darcy has established herself as a thought leader in the field of pediatric vascular access, authoring clinical guidelines, facil
Jun 27, 2023 07:30 am ET
Covalon Announces Participation in Oley Conference in St. Louis, Missouri on June 27 – 30, 2023
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the 2023 Annual Oley Foundation Conference being held in St. Louis, Missouri from Tuesday, June 27 to Friday, June 30, 2023. Patients, caregivers, healthcare providers, and advocates looking for more compassionate care solutions for those living with intravenous therapies should visit Covalon at booth 307 to learn more about Covalon’s unique position to provide “apology-free” dressings that are gentle on skin.
Jun 26, 2023 07:30 am ET
Covalon Announces Participation in APIC Annual Conference & Exposition on June 26 – 28, 2023 in Orlando, Florida
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it is participating in the 2023 APIC Annual Conference and Exposition in Orlando, Florida from June 26 to 28, 2023. Healthcare providers looking to strengthen their infection prevention toolkit with patient-centered medical technology should visit Covalon at booth 612 to learn more about Covalon’s unique compassionate care solutions.
Jun 21, 2023 07:30 am ET
Webinar on Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention, Presented by Covalon
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced an expert-led webinar titled “Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention” will be held on Thursday, June 22, 2023 at 1pm ET.
Jun 13, 2023 07:30 am ET
Breakthrough Solution for Fragile Skin: Covalon’s IV Clear® Dressing Recommended by Physicians at a Top 10 U.S. Children’s Hospital and Epidermolysis Bullosa Center of Excellence
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that its IV Clear® line of dual antimicrobial silicone dressings has been recommended by physicians at a Top 10 U.S. Children’s Hospital in Colorado, which is also an EB (“Epidermolysis Bullosa”) Center of Excellence, as a novel solution to effectively secure and protect vascular access insertion sites on patients with fragile skin, including those with EB.
May 25, 2023 07:00 am ET
Covalon Announces Second Quarter Results for Fiscal 2023
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its second quarter fiscal 2023 results.
May 23, 2023 07:00 am ET
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2023 Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2023 financial results on Thursday, May 25, 2023, before markets open. A conference call and webcast to discuss the financial results will be held on Thursday, May 25, 2023, at 9:00am EST.
May 16, 2023 07:30 am ET
Covalon, Leader in Compassionate Pediatric Infection Prevention Solutions, to Participate in Neonatal/Fetal Conference in Columbus, Ohio on May 17 - 19, 2023
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced it is a silver sponsor of the 2023 Neonatal/Fetal Conference: From the Womb and Beyond being held both virtually and in-person in Columbus, Ohio from May 17 to 19, 2023. Healthcare providers looking for more compassionate care solutions for pediatric patients should visit Covalon at exhibit 106 to learn more about Covalon’s unique position to provide “apology-free” dressings.
Apr 26, 2023 10:05 am ET
Compassionate Care Solutions Provider Covalon Participating in the Canadian Vascular Access Association and World Congress on Vascular Access Joint Conference on April 26-28, 2023 in Toronto
MISSISSAUGA, ON, April 26, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its attendance at the 48th Annual Canadian Vascular Access Association (CVAA) Conference and World Congress on Vascular Access (WoCoVA) Special Event from Wednesday, April 26 to Friday, April 28, 2023 in Toronto, Canada.
Apr 26, 2023 10:05 am ET
Compassionate Care Solutions Provider Covalon Participating in the Canadian Vascular Access Association and World Congress on Vascular Access Joint Conference on April 26-28, 2023 in Toronto
MISSISSAUGA, ON, April 26, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its attendance at the 48th Annual Canadian Vascular Access Association (CVAA) Conference and World Congress on Vascular Access (WoCoVA) Special Event from Wednesday, April 26 to Friday, April 28, 2023 in Toronto, Canada.
Mar 27, 2023 07:30 am ET
Covalon Presents New CLABSI Conscious Series Webinar: Protecting CVADs from Gross Contamination
Registration now open: A case by case review of innovative and practical solutions for preventing CLABSI
Mar 27, 2023 07:30 am ET
Covalon Presents New CLABSI Conscious Series Webinar: Protecting CVADs from Gross Contamination
Registration now open: A case by case review of innovative and practical solutions for preventing CLABSI
Mar 20, 2023 07:00 am ET
Leader in Compassionate Care Infection Prevention Solutions, Covalon, to Participate in the Synova NICU Leadership Forum 2023 in Tucson, Arizona from March 19 to 23, 2023
Visit booth 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutions.
Mar 20, 2023 07:00 am ET
Leader in Compassionate Care Infection Prevention Solutions, Covalon, to Participate in the Synova NICU Leadership Forum 2023 in Tucson, Arizona from March 19 to 23, 2023
Visit booth 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutions.
Mar 09, 2023 07:00 am ET
Covalon Announces Voting Results from Fiscal 2022 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, March 9, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2022 Annual and Special Meeting of Shareholders ("AGM") held March 8, 2023.
Mar 09, 2023 07:00 am ET
Covalon Announces Voting Results from Fiscal 2022 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2022 Annual and Special Meeting of Shareholders ("AGM") held March 8, 2023.
Mar 09, 2023 06:00 am ET
Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors
MISSISSAUGA, ON, March 9, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.
Mar 09, 2023 06:00 am ET
Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors
MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.
Feb 28, 2023 06:00 am ET
Covalon To Hold Annual and Special Meeting of Shareholders on Wednesday, March 8, 2023
MISSISSAUGA, ON, Feb. 28, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, has announced that the annual and special meeting of shareholders of the Company will be held on Wednesday, March 8, 2023 at 3:30pm EST in a virtual-only format where shareholders may attend and participate in the meeting via live webcast.
Feb 23, 2023 06:00 am ET
Covalon Announces Improved First Quarter Fiscal 2023 Results
Revenue growth of 25%, significant margin improvement and strong balance sheet
Feb 20, 2023 09:01 am ET
Infection Prevention Solutions Provider Covalon to Participate for the First Time in NEO - The Conference for Neonatology in Las Vegas, NV on February 22-24, 2023
Visit booth 100 to learn how Covalon's products are uniquely designed to help prevent CLABSIs and SSIs while providing more gentle, compassionate experiences for neonates and young children.
Feb 20, 2023 09:01 am ET
Infection Prevention Solutions Provider Covalon to Participate for the First Time in NEO - The Conference for Neonatology in Las Vegas, NV on February 22-24, 2023
Visit booth 100 to learn how Covalon's products are uniquely designed to help prevent CLABSIs and SSIs while providing more gentle, compassionate experiences for neonates and young children.
Feb 17, 2023 05:01 pm ET
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2023 Financial Results
MISSISSAUGA, ON, Feb. 17, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open. A conference call and webcast to discuss the financial results will be held on Thursday, February 23, 2023, at 9:00am EST.
Feb 17, 2023 05:01 pm ET
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2023 Financial Results
MISSISSAUGA, ON, Feb. 17, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open. A conference call and webcast to discuss the financial results will be held on Thursday, February 23, 2023, at 9:00am EST.
Jan 25, 2023 08:15 pm ET
Covalon Announces Fourth Quarter and Year End Results for Fiscal 2022 and Highlights Company Transformation Changes
MISSISSAUGA, ON, Jan. 25, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.
Jan 25, 2023 08:15 pm ET
Covalon Announces Fourth Quarter and Year End Results for Fiscal 2022 and Highlights Company Transformation Changes
MISSISSAUGA, ON, Jan. 25, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.
Jan 23, 2023 06:00 am ET
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2022 Financial Results
MISSISSAUGA, ON, Jan. 23, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2022 financial results on Wednesday, January 25th, 2023, after markets close. A conference call and webcast to discuss the financial results will be held on Thursday, January 26th, 2023 at 9:00am EST.
Jan 23, 2023 06:00 am ET
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2022 Financial Results
MISSISSAUGA, ON, Jan. 23, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2022 financial results on Wednesday, January 25th, 2023, after markets close. A conference call and webcast to discuss the financial results will be held on Thursday, January 26th, 2023 at 9:00am EST.
Nov 21, 2022 09:01 am ET
Covalon's SurgiClear Dressing Plays an Important Part in Preventing Surgical Wound Infections at Top Children's Hospital
A two-year study with the aim of preventing sternal wound infections highlights SurgiClear as a key component of the infection prevention bundle used to significantly reduce infection rates
Nov 21, 2022 09:01 am ET
Covalon's SurgiClear Dressing Plays an Important Part in Preventing Surgical Wound Infections at Top Children's Hospital
A two-year study with the aim of preventing sternal wound infections highlights SurgiClear as a key component of the infection prevention bundle used to significantly reduce infection rates
Nov 08, 2022 09:01 am ET
Covalon Launches New "CLABSI Conscious" Campaign to Help Children Heal Without Infections
Amongst a climbing Central Line Associated Blood Stream Infection ("CLABSI") rate across the United States, Covalon is releasing new digital resources focused on the role of technology to strengthen and reinforce infection prevention practices.
Nov 08, 2022 09:01 am ET
Covalon Launches New "CLABSI Conscious" Campaign to Help Children Heal Without Infections
Amongst a climbing Central Line Associated Blood Stream Infection ("CLABSI") rate across the United States, Covalon is releasing new digital resources focused on the role of technology to strengthen and reinforce infection prevention practices.
Nov 01, 2022 10:01 am ET
Closing Chronic Wounds with Collagen Powder: University of Michigan case study demonstrates the efficacy of ColActive Plus Powder in resolving non-healing wounds
Evidence on Covalon's New ColActive Plus Powder presented at the Symposium on Advanced Wound Care
Nov 01, 2022 10:01 am ET
Closing Chronic Wounds with Collagen Powder: University of Michigan case study demonstrates the efficacy of ColActive Plus Powder in resolving non-healing wounds
Evidence on Covalon's New ColActive Plus Powder presented at the Symposium on Advanced Wound Care
Oct 11, 2022 11:59 am ET
Covalon to Participate in the American Nurses Credentialing Center Magnet Conference in Philadelphia
Visit Covalon at booth 1557 from October 13 to October 15, 2022 at the Pennsylvania Convention Center
Oct 11, 2022 11:59 am ET
Covalon to Participate in the American Nurses Credentialing Center Magnet Conference in Philadelphia
Visit Covalon at booth 1557 from October 13 to October 15, 2022 at the Pennsylvania Convention Center
Sep 28, 2022 10:01 am ET
Covalon to Participate in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto
Visit Covalon to learn how new compassionate care technology is protecting patients from infections, while strengthening patient-centered care.
Sep 28, 2022 10:01 am ET
Covalon to Participate in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto
Visit Covalon to learn how new compassionate care technology is protecting patients from infections, while strengthening patient-centered care.
Sep 26, 2022 10:59 am ET
Covalon to Showcase Infection Prevention Solutions at the Association for Vascular Access Annual Scientific Meeting
Book an appointment with us and visit booth 607 at the Minneapolis Convention Center from September 30 to October 2 to learn more
Sep 26, 2022 10:59 am ET
Covalon to Showcase Infection Prevention Solutions at the Association for Vascular Access Annual Scientific Meeting
Book an appointment with us and visit booth 607 at the Minneapolis Convention Center from September 30 to October 2 to learn more
Sep 20, 2022 09:10 am ET
Covalon's Dual Antimicrobial Surgical Site Dressing Adopted by Leading US Pediatric Hospital's Congenital Heart Program
Advanced post-operative dressing is now used to prevent post-operative infections in patients with congenital heart conditions from birth through adulthood.
Sep 20, 2022 09:10 am ET
Covalon's Dual Antimicrobial Surgical Site Dressing Adopted by Leading US Pediatric Hospital's Congenital Heart Program
Advanced post-operative dressing is now used to prevent post-operative infections in patients with congenital heart conditions from birth through adulthood.
Sep 13, 2022 10:01 am ET
Covalon to Introduce New Infection Prevention Products at the Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference
Ensuring that health professionals caring for the youngest patients have access to advanced wound care and infection prevention solutions
Sep 13, 2022 10:01 am ET
Covalon to Introduce New Infection Prevention Products at the Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference
Ensuring that health professionals caring for the youngest patients have access to advanced wound care and infection prevention solutions
Sep 08, 2022 08:00 am ET
Covalon Announces Expansion of its United States Pediatric Hospital Customer Base
Covalon's compassionate care technology is quickly becoming a standard of care in more than 17% of pediatric hospitals in the US.
Sep 08, 2022 08:00 am ET
Covalon Announces Expansion of its United States Pediatric Hospital Customer Base
Covalon's compassionate care technology is quickly becoming a standard of care in more than 17% of pediatric hospitals in the US.
Sep 07, 2022 07:00 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, Sept. 7, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 437,500 common shares ("Common Shares") to certain of its employees. All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.
Sep 07, 2022 07:00 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, Sept. 7, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 437,500 common shares ("Common Shares") to certain of its employees. All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.
Aug 29, 2022 07:00 am ET
Covalon Announces Third Quarter Fiscal 2022 Results
MISSISSAUGA, ON, Aug. 29, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2022 results.
Aug 29, 2022 07:00 am ET
Covalon Announces Third Quarter Fiscal 2022 Results
MISSISSAUGA, ON, Aug. 29, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2022 results.
Aug 24, 2022 07:00 am ET
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, Aug. 24, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2022 financial results on Monday, August 29th, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Monday, August 29th, 2022, at 9:00am EST.
Aug 24, 2022 07:00 am ET
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, Aug. 24, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2022 financial results on Monday, August 29th, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Monday, August 29th, 2022, at 9:00am EST.
Jun 30, 2022 08:43 am ET
Covalon Enters into Automatic Share Purchase Plan
MISSISSAUGA, ON, June 30, 2022 /CNW/ - Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that it has entered into an automatic share purchase plan (the "Plan") with PI Financial Corp. (the "Broker") in order to facilitate repurchases of the Company's common shares (the "Shares") under its previously announced normal course issuer bid (the "NCIB"). The ASPP has been approved by the TSX Venture Exchange (the "TSXV") and will be implemented effective as of June 29, 2022.
Jun 30, 2022 08:43 am ET
Covalon Enters into Automatic Share Purchase Plan
MISSISSAUGA, ON, June 30, 2022 /PRNewswire/ - Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that it has entered into an automatic share purchase plan (the "Plan") with PI Financial Corp. (the "Broker") in order to facilitate repurchases of the Company's common shares (the "Shares") under its previously announced normal course issuer bid (the "NCIB"). The ASPP has been approved by the TSX Venture Exchange (the "TSXV") and will be implemented effective as of June 29, 2022.
May 30, 2022 07:00 am ET
Covalon Announces Second Quarter Fiscal 2022 Results
MISSISSAUGA, ON, May 30, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its second quarter fiscal 2022 results.
May 30, 2022 07:00 am ET
Covalon Announces Second Quarter Fiscal 2022 Results
MISSISSAUGA, ON, May 30, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its second quarter fiscal 2022 results.
May 26, 2022 07:00 am ET
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, May 26, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTC: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2022 financial results on Monday May 30th, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Monday May 30th, 2022, at 9:00am EST.
May 26, 2022 07:00 am ET
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, May 26, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTC: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2022 financial results on Monday May 30th, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Monday May 30th, 2022, at 9:00am EST.
May 25, 2022 07:00 am ET
COVALON TECHNOLOGIES LTD. ANNOUNCES NORMAL COURSE ISSUER BID
MISSISSAUGA, ON, May 25, 2022 /CNW/ - Covalon Technologies Ltd. (TSXV: COV) (OTCQX: CVALF) (the "Company" or "Covalon"), an advanced medical technologies company, today announced that it has filed its intention to make a normal course issuer bid (the "NCIB") for its common shares with the TSX Venture Exchange (the "Exchange" or "TSXV"). The NCIB remains subject to regulatory approval.
May 19, 2022 11:27 am ET
Covalon Attracts Well-Known Medical Industry Sales Executive
MISSISSAUGA, ON, May 19, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales.
May 19, 2022 11:27 am ET
Covalon Attracts Well-Known Medical Industry Sales Executive
MISSISSAUGA, ON, May 19, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Mark Doolittle has joined the Company as Senior Vice President, Commercial Sales.
Apr 26, 2022 07:00 am ET
Covalon Announces New Senior Vice President of Marketing
MISSISSAUGA, ON, April 26, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Ron Hebert has joined the Company as Senior Vice President of Marketing.
Apr 26, 2022 07:00 am ET
Covalon Announces New Senior Vice President of Marketing
MISSISSAUGA, ON, April 26, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Ron Hebert has joined the Company as Senior Vice President of Marketing.
Mar 29, 2022 09:21 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, March 29, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 507,500 common shares ("Common Shares") to certain of its directors, officers, employees, and consultants. All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the requirements o
Mar 29, 2022 09:21 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, March 29, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce that the Company's Board of Directors has approved the grant of stock options (the "Options") exercisable for a total of 507,500 common shares ("Common Shares") to certain of its directors, officers, employees, and consultants. All Options were granted pursuant to the Company's amended and restated stock option plan and are subject to the terms of the applicable grant agreements and the require
Mar 10, 2022 07:00 am ET
Covalon Announces Voting Results from Fiscal 2021 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, March 10, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today the results of the matters voted upon at its Fiscal 2021 Annual and Special Meeting of Shareholders ("AGM") held March 9th, 2022.
Mar 10, 2022 07:00 am ET
Covalon Announces Voting Results from Fiscal 2021 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, March 10, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today the results of the matters voted upon at its Fiscal 2021 Annual and Special Meeting of Shareholders ("AGM") held March 9th, 2022.
Mar 10, 2022 06:00 am ET
Covalon Announces Changes to its Board of Directors
Dr. Samantha Nutt has Been Elected to Covalon's BoardMr. Martin Goldfarb has Retired from Covalon's BoardMISSISSAUGA, ON, March 10, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Dr. Samantha Nutt has been elected a Director subject to TSX approval and Mr. Martin Goldfarb has retired as a Director of the Covalon Board.
Mar 10, 2022 06:00 am ET
Covalon Announces Changes to its Board of Directors
Dr. Samantha Nutt has Been Elected to Covalon's BoardMr. Martin Goldfarb has Retired from Covalon's BoardMISSISSAUGA, ON, March 10, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Dr. Samantha Nutt has been elected a Director subject to TSX approval and Mr. Martin Goldfarb has retired as a Director of the Covalon Board.
Mar 01, 2022 06:00 am ET
Covalon Announces First Quarter Fiscal 2022 Results
MISSISSAUGA, ON, March 1, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its first quarter fiscal 2022 results.
Mar 01, 2022 06:00 am ET
Covalon Announces First Quarter Fiscal 2022 Results
MISSISSAUGA, ON, March 1, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its first quarter fiscal 2022 results.
Feb 16, 2022 11:27 am ET
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, Feb. 16, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2022 financial results on Tuesday March 1st, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Tuesday, March 1st, 2022, at 9:00am EST.
Feb 16, 2022 11:27 am ET
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2022 Financial Results
MISSISSAUGA, ON, Feb. 16, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2022 financial results on Tuesday March 1st, 2022, before markets open. A conference call and webcast to discuss the financial results will be held on Tuesday, March 1st, 2022, at 9:00am EST.
Jan 14, 2022 07:00 am ET
Covalon Announces Appointment of Interim CFO
MISSISSAUGA, ON, Jan. 14, 2022 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that it has appointed Jason F. Gorel as its interim Chief Financial Officer. Mr. Gorel has been appointed interim Chief Financial Officer while the Company undertakes a search for a new Chief Financial Officer to assist Covalon with its next phase of growth.
Jan 14, 2022 07:00 am ET
Covalon Announces Appointment of Interim CFO
MISSISSAUGA, ON, Jan. 14, 2022 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that it has appointed Jason F. Gorel as its interim Chief Financial Officer. Mr. Gorel has been appointed interim Chief Financial Officer while the Company undertakes a search for a new Chief Financial Officer to assist Covalon with its next phase of growth.
Dec 24, 2021 06:00 am ET
Covalon Announces CFO Transition
MISSISSAUGA, ON, Dec. 24, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Danny Brannagan, its Chief Financial Officer, will be stepping down in January 2022 to pursue other endeavours. The Company intends to appoint an interim Chief Financial Officer while it undertakes a search for a new Chief Financial Officer with a proven track record of financial leadership and experience to help Covalon with its next phase of growth.
Dec 24, 2021 06:00 am ET
Covalon Announces CFO Transition
MISSISSAUGA, ON, Dec. 24, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced that Danny Brannagan, its Chief Financial Officer, will be stepping down in January 2022 to pursue other endeavours. The Company intends to appoint an interim Chief Financial Officer while it undertakes a search for a new Chief Financial Officer with a proven track record of financial leadership and experience to help Covalon with its next phase of growth.
Dec 13, 2021 06:00 am ET
Covalon Announces Strong Year End and Fourth Quarter Results for Fiscal 2021
Year-end net profit of $23.5 million or $0.91 per share which includes net income from the sale of the AquaGuard operations Revenue from continuing operations increased 45% to $19.6 million for the year, compared to $13.5 million in the prior year due to an increase in product sales Fourth quarter was profitable with net income of $1.0 million or $0.04 per share and Adjusted EBITDA of $1.8 million from continuing operations Covalon ended the year with $25.5 million of cash or $0.99 per share on the balance sheet with all debt repaid MISSISSAUGA, ON, Dec. 13, 2021 /PRNewswire/ - Covalon Tech
Dec 13, 2021 06:00 am ET
Covalon Announces Strong Year End and Fourth Quarter Results for Fiscal 2021
Year-end net profit of $23.5 million or $0.91 per share which includes net income from the sale of the AquaGuard operations Revenue from continuing operations increased 45% to $19.6 million for the year, compared to $13.5 million in the prior year due to an increase in product sales Fourth quarter was profitable with net income of $1.0 million or $0.04 per share and Adjusted EBITDA of $1.8 million from continuing operations Covalon ended the year with $25.5 million of cash or $0.99 per share on the balance sheet with all debt repaid MISSISSAUGA, ON, Dec. 13, 2021 /CNW/ - Covalon Technologie
Dec 08, 2021 04:41 pm ET
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2021 Financial Results
MISSISSAUGA, ON, Dec. 8, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2021 financial results on Monday, December 13, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, December 13, 2021 at 9:00am EST. To participate in the conference call, please dial:
Dec 08, 2021 04:41 pm ET
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2021 Financial Results
MISSISSAUGA, ON, Dec. 8, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2021 financial results on Monday, December 13, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, December 13, 2021 at 9:00am EST. To participate in the conference call, please dial:
Sep 24, 2021 08:00 am ET
Covalon Announces Retirement of Board Member
MISSISSAUGA, ON, Sept. 24, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announces that Dr. Myrna Francis is retiring as a member of the Board of Directors of the Company, effective September 24th, 2021, due to new professional commitments that will prevent her from continuing to commit time to Covalon.
Aug 30, 2021 08:00 am ET
Covalon Announces Fiscal 2021 Q3 Results
MISSISSAUGA, ON, Aug. 30, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2021 third quarter results for the period ended June 30, 2021.
Aug 30, 2021 08:00 am ET
Covalon Announces Fiscal 2021 Q3 Results
MISSISSAUGA, ON, Aug. 30, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2021 third quarter results for the period ended June 30, 2021.
Aug 26, 2021 03:49 pm ET
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2021 Financial Results
MISSISSAUGA, ON, Aug. 26, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2021 financial results on Monday, August 30, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, August 30, 2021 at 9:00am EST. To participate in the conference call, please dial:
Aug 26, 2021 03:49 pm ET
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2021 Financial Results
MISSISSAUGA, ON, Aug. 26, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2021 financial results on Monday, August 30, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, August 30, 2021 at 9:00am EST. To participate in the conference call, please dial:
Jul 29, 2021 10:01 am ET
IIROC Trading Resumption - COV
VANCOUVER, BC, July 29, 2021 /CNW/ - Trading resumes in:
Jul 29, 2021 09:38 am ET
Covalon Announces Sale of its AquaGuard® Product Line for US$30 Million or Approximately CDN$38 Million
Purchase and sale agreement executed with simultaneous closing with TIDI Products, LLC as buyer The transaction materially improves Covalon's balance sheet to an estimated net cash position of approximately CDN$24 million or CDN$0.93 per share after repayment of all outstanding debt The sale results in a net gain, prior to transaction expenses, of approximately CDN$20 million or CDN$0.77 per share on an after-tax basis over what Covalon paid for the AquaGuard business approximately 3 years ago AquaGuard's customers and distribution partners are expected to benefit from TIDI's current extensi
Jul 29, 2021 08:47 am ET
IIROC Trading Halt - COV
VANCOUVER, BC, July 29, 2021 /CNW/ - The following issues have been halted by IIROC:
Jul 02, 2021 07:00 am ET
Covalon Announces Voting Results from Fiscal 2020 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, July 2, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today the results of the matters voted upon at its Fiscal 2020 Annual and Special Meeting of Shareholders ("AGM") held June 30th, 2021.
Jul 02, 2021 07:00 am ET
Covalon Announces Voting Results from Fiscal 2020 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, July 2, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today the results of the matters voted upon at its Fiscal 2020 Annual and Special Meeting of Shareholders ("AGM") held June 30th, 2021.
May 31, 2021 07:00 am ET
Covalon Announces Fiscal 2021 Q2 Results
MISSISSAUGA, ON, May 31, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2021 second quarter results for the period ended March 31, 2021.
May 27, 2021 08:30 am ET
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2021 Financial Results
MISSISSAUGA, ON, May 27, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2021 financial results on Monday, May 31st, 2021 before markets open. A conference call to discuss the financial results will be held on Monday, May 31st, 2021 at 9:00am EST. To participate in the conference call, please dial:
Mar 01, 2021 06:00 am ET
Covalon Announces First Quarter Fiscal 2021 Results
MISSISSAUGA, ON, March 1, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announced its first quarter fiscal 2021 results.
Feb 26, 2021 02:46 pm ET
Covalon Announces Conference Call to Discuss First Quarter Financial Results
MISSISSAUGA, ON, Feb. 26, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its fiscal 2021 first quarter financial results on Monday March 1st 2021 before markets open. A conference call to discuss the financial results will be held on Monday March 1st 2021 at 9:00am EST. To participate in the conference call, please dial:
Jan 28, 2021 06:00 am ET
Covalon Announces Fiscal 2020 Year-End Results
MISSISSAUGA, ON, Jan. 28, 2021 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announces its fiscal 2020 year-end results for the year ended September 30, 2020.
Jan 28, 2021 06:00 am ET
Covalon Announces Fiscal 2020 Year-End Results
MISSISSAUGA, ON, Jan. 28, 2021 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today announces its fiscal 2020 year-end results for the year ended September 30, 2020.
Nov 13, 2020 06:30 am ET
Covalon Announces Appointment of Amir Boloor as Board Chair and Voting Results from Fiscal 2019 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, Nov. 13, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce the appointment of Amir Boloor, President of Caspian Equity Partners, Inc., as Chair of the Company's Board of Directors. Mr. Boloor, an independent director of the Company, is also Chair of the Company's recently announced Special Committee, appointed to explore and evaluate a range of strategic alternatives available to the Company in order to enhance shareholder value.
Nov 13, 2020 06:30 am ET
Covalon Announces Appointment of Amir Boloor as Board Chair and Voting Results from Fiscal 2019 Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, Nov. 13, 2020 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, today is pleased to announce the appointment of Amir Boloor, President of Caspian Equity Partners, Inc., as Chair of the Company's Board of Directors. Mr. Boloor, an independent director of the Company, is also Chair of the Company's recently announced Special Committee, appointed to explore and evaluate a range of strategic alternatives available to the Company in order to enhance shareholder value.
Oct 21, 2020 09:10 am ET
Covalon Initiates Strategic Review to Enhance Shareholder Value
MISSISSAUGA, ON, Oct. 21, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today that its Board of Directors has initiated a process to explore and evaluate a range of strategic alternatives available to the Company (the "Strategic Review") in order to enhance shareholder value.
Oct 21, 2020 09:10 am ET
Covalon Initiates Strategic Review to Enhance Shareholder Value
MISSISSAUGA, ON, Oct. 21, 2020 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced today that its Board of Directors has initiated a process to explore and evaluate a range of strategic alternatives available to the Company (the "Strategic Review") in order to enhance shareholder value.
Aug 24, 2020 07:00 am ET
Covalon Announces Third Quarter Fiscal 2020 Results
MISSISSAUGA, ON, Aug. 24, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV); (OTCQX: CVALF), an advanced medical technologies company, today announces its third quarter fiscal 2020 results.
Aug 21, 2020 09:50 pm ET
Covalon Announces Conference Call to Discuss Third Quarter Financial Results
MISSISSAUGA, ON, Aug. 21, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2020 Third Quarter financial results on Monday August 24th, 2020, before markets open.
Jul 14, 2020 05:30 pm ET
Covalon Announces Second Quarter Fiscal 2020 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announces its second quarter fiscal 2020 results.
Jun 30, 2020 07:30 am ET
Covalon Provides Business Update
MISSISSAUGA, ON, June 30, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, provides today an update on material business developments per Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements. The Company continues to rely on the exemption provided in the aforementioned instrument to postpone the filing of the interim financial statements and management's discussion and analysis for the quarter ended March 31, 2020 (the "Documents"). The Company expects to file the D
Jun 30, 2020 07:30 am ET
Covalon Provides Business Update
MISSISSAUGA, ON, June 30, 2020 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, provides today an update on material business developments per Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements. The Company continues to rely on the exemption provided in the aforementioned instrument to postpone the filing of the interim financial statements and management's discussion and analysis for the quarter ended March 31, 2020 (the "Documents"). The Company expects to fil
Jun 03, 2020 07:30 am ET
Covalon Granted Key Antimicrobial Patents in the United States, Canada, and Europe
MISSISSAUGA, ON, June 3, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that the Company has been granted key antimicrobial patents by the United States Patent and Trademark Office ("USPTO"), the Canadian Intellectual Property Office ("CIPO"), and the European Patent Office ("EPO").
Jun 03, 2020 07:30 am ET
Covalon Granted Key Antimicrobial Patents in the United States, Canada, and Europe
MISSISSAUGA, ON, June 3, 2020 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that the Company has been granted key antimicrobial patents by the United States Patent and Trademark Office ("USPTO"), the Canadian Intellectual Property Office ("CIPO"), and the European Patent Office ("EPO").
May 29, 2020 05:30 pm ET
Covalon Delays Filing of Interim Financial Statements Due to Delays Related to COVID-19 and Provides Business Update
MISSISSAUGA, ON, May 29, 2020 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today that it is relying on the exemption provided in Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements (and similar exemptions provided by the other Canadian securities regulators) to postpone the filing of the interim financial statements and management's discussion and analysis for the quarter ended March 31st, 2020. The Company expects to file the Documents within the 45-day po
May 29, 2020 05:30 pm ET
Covalon Delays Filing of Interim Financial Statements Due to Delays Related to COVID-19 and Provides Business Update
MISSISSAUGA, ON, May 29, 2020 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announced today that it is relying on the exemption provided in Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements (and similar exemptions provided by the other Canadian securities regulators) to postpone the filing of the interim financial statements and management's discussion and analysis for the quarter ended March 31st, 2020. The Company expects to file the Documents within the 45
Apr 27, 2020 07:30 am ET
Amir Boloor Joins Covalon’s Board of Directors
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is delighted to announce that Mr. Amir Boloor has joined its Board of Directors.
Apr 23, 2020 07:30 am ET
Martin Goldfarb, O.C., Joins Covalon’s Board of Directors
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is delighted to announce that Mr. Martin Goldfarb has joined its Board of Directors.
Apr 14, 2020 05:00 pm ET
Covalon Postpones Annual Meeting of Shareholders Due to COVID-19
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces today that given the extraordinary circumstances of the ongoing COVID-19 pandemic and the resulting restrictions on public gatherings, it is postponing its annual meeting of shareholders to a later date.
Apr 03, 2020 01:47 pm ET
Covalon Announces Conference Call to Discuss New CovaGuard Antimicrobial Technology
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces a conference call to further discuss its new CovaGuard antimicrobial technology.
Apr 01, 2020 09:01 am ET
IIROC Trading Resumption - COV
VANCOUVER, April 1, 2020 /CNW/ - Trading resumes in:
Mar 31, 2020 05:18 pm ET
Covalon Clarifies Previous Press Release
At the request of IIROC, Investment Industry Regulatory Organization of Canada, Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has been asked to clarify the press release issued earlier today. At IIROC’s request, the Company retracts the title to its last press release because IIROC has deemed the title overly promotional. At IIROC’s request, the Company modifies the title to “Covalon Announces New Antimicrobial Technology”.
Mar 31, 2020 09:47 am ET
IIROC Trading Halt - COV
VANCOUVER, March 31, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 31, 2020 07:30 am ET
Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces today its new breakthrough antimicrobial technology formulated to kill the COVID-19 virus (or “SARS-CoV-2”) and other viruses, bacteria, and pathogens.
Mar 02, 2020 05:30 pm ET
Covalon Announces First Quarter Fiscal 2020 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announces its first quarter fiscal 2020 results.
Feb 28, 2020 05:59 pm ET
Covalon Announces Conference Call to Discuss First Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2020 First Quarter financial results on Monday, March 2nd, 2020, after markets close. A conference call to discuss the financial results will be held Tuesday, March 3rd, 2020 at 9:00am EST. To participate in the conference call, please dial:
Jan 28, 2020 05:00 pm ET
Covalon Announces Fiscal 2019 Year-End Results and Plans for Fiscal 2020
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announces its fiscal 2019 year-end results and plans for fiscal 2020.
Jan 27, 2020 12:51 pm ET
Covalon Announces Conference Call to Discuss Year-End and Fourth Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Fiscal 2019 Fourth Quarter and Year-End financial results concurrently on Tuesday, January 28th, 2020 after markets close. A conference call to discuss the financial results will be held on Wednesday, January 29th, 2020 at 9:00am EST. To participate in the conference call, please dial:
Sep 18, 2019 06:02 pm ET
Covalon Announces Closing of Non-Brokered Private Placement
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that, further to its press release dated September 6, 2019, it has completed a non-brokered private placement offering comprised of approximately 2,750,000 units (each, a “Unit”) of the Corporation at a price of $2.00 per Unit for aggregate gross proceeds of approximately $5,500,000 (the “Offering”).
Sep 06, 2019 05:00 pm ET
Covalon Announces Re-Pricing of Private Placement
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has re-priced its non-brokered private placement originally announced on August 1, 2019 (the "Offering"). The Offering is being re-priced in order to more accurately reflect the current market price of the Company’s common shares.
Aug 27, 2019 05:30 pm ET
Covalon Announces Third Quarter Fiscal 2019 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its third quarter fiscal 2019 results.
Aug 01, 2019 07:00 am ET
Covalon Announces Private Placement of Up To $6.3 Million
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that the Company intends to raise up to an aggregate of $6.3 million in one or more closings (the “Offering”).
Jul 25, 2019 07:00 am ET
Covalon CEO Provides Corporate Update
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, wishes to provide the following corporate update:
May 28, 2019 06:26 pm ET
Covalon Announces Second Quarter Fiscal 2019 Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, today announced
its second quarter fiscal 2019 results.
May 27, 2019 10:32 am ET
Covalon Announces Conference Call to Discuss Second Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, will be
releasing its Fiscal 2019 Second Quarter financial results on Tuesday
May 28th, 2019, after markets close. A conference call to
discuss the financial results will be held Wednesday May 29th,
2019, at 9:00am EST. To participate in the conference call, please dial:
Apr 08, 2019 08:00 am ET
Covalon’s Award-Winning MediClear PreOp Product Recognized as Innovative Solution to Help Hospitals Reduce Surgical Site Infections
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF) is pleased to announce that its MediClear™ PreOp product
has been recognized by both the medical device industry and by key
clinicians as an important innovation in the fight to
prevent surgical site infections.
Mar 18, 2019 08:00 am ET
Mr. Ron Smith Joins Covalon’s Board of Directors and is Appointed Chair of the Audit Committee
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, today announced
that Mr. Ron Smith has joined Covalon’s Board of Directors and has been
appointed Chair of Covalon’s Audit Committee.
Mar 08, 2019 07:00 am ET
Covalon Announces Voting Results from 2019 Annual and Special Meeting of Shareholders
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, today announces
the results of the matters voted upon at the Company’s 2019 Annual and
Special Meeting of Shareholders on held March 7, 2019.
Feb 26, 2019 05:30 pm ET
Covalon Announces First Quarter Fiscal 2019 Results and Updates Plans for Fiscal 2019
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
its first quarter fiscal 2019 results and updated its plans for fiscal
2019.
Feb 21, 2019 05:00 pm ET
Covalon Announces Conference Call to Discuss First Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, will be
releasing its Fiscal 2019 First Quarter financial results on Tuesday
February 26th, 2019, after markets close. A conference call
to discuss the financial results will be held Wednesday February 27th,
2019, at 9:00am EST. To participate in the conference call, please dial:
Jan 30, 2019 08:00 am ET
Mr. John Suk Joins Covalon’s Board of Directors
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that Mr. John Suk has joined Covalon’s Board of Directors.
Jan 28, 2019 08:00 am ET
Dr. Myrna Francis Joins Covalon’s Board of Directors
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that Dr. Myrna Francis has joined Covalon’s Board of Directors.
Jan 24, 2019 05:30 pm ET
Covalon Announces Change of Auditors and Amends and Restates Its Rolling Stock Option Plan
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, announced today
that it has appointed PricewaterhouseCoopers LLP (“Successor Auditor”)
as its auditor. At the request of the Company, BDO Canada LLP (“Former
Auditor”) resigned as the auditor of the Company, effective January 21,
2019, and the Board of Directors of the Company appointed the Successor
Auditor as the Company's auditor, effective January 21, 2019, until the
next Annual General Meeting of the Company.
Dec 27, 2018 08:00 am ET
Covalon Announces Issuance of Stock Options
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announces
the issuance of an aggregate of 425,000 stock options to staff of the
Company. The stock options will vest over three years and will be
exercisable for a period of five years at an exercise price of $4.28 per
stock option.
Dec 17, 2018 05:00 pm ET
Covalon Announces Fiscal 2018 Year-End Results and Plans for Fiscal 2019
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announces
its fiscal 2018 year-end results and plans for fiscal 2019.
Dec 17, 2018 08:00 am ET
Covalon Announces Conference Call to Discuss Year-End and Fourth Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, will release its
Fiscal 2018 Fourth Quarter and Year-End financial results concurrently
on Monday December 17th, 2018, after markets close. A
conference call to discuss the financial results will be held Tuesday
December 18th, 2018, at 9:00am EST. To participate in the
conference call, please dial:
Oct 30, 2018 08:00 am ET
Covalon Announces Successful Completion of Operational Integration of AquaGuard Acquisition amid Continued Business Progress
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announces
that it has successfully completed the integration of AquaGuard with its
operations.
Oct 24, 2018 08:00 am ET
Covalon to Showcase AquaGuard® and IV Clear™ Products to Over 9,000 Nurses at Prestigious ANCC Magnet Conference
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV)
(OTCQX:CVALF), an advanced medical technologies company, today announces
that it will be showcasing newly-acquired moisture barrier line AquaGuard®
as part of its portfolio of infection prevention products at the 2018
American Nurses Credentialing Center National Magnet Conference (the
“Magnet Conference”). The Magnet Conference will take place at the
Colorado Convention Centre in Denver, Colorado, from October 24th
to 26th 2018, and will be Covalo
Oct 01, 2018 05:58 pm ET
Covalon Announces Closing of AquaGuard Acquisition Combining Covalon’s Rich Technology Portfolio with AquaGuard’s Excellent Products and Specialized Salesforce Capable of Selling Covalon’s Products Th
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it has closed the acquisition (the “Closing”) of AquaGuard,
the Seattle, Washington-based division of medical technologies company
Cenorin, LLC. AquaGuard's specialized products provide patients with
crucial moisture protection for wound, surgical, and vascular access
sites throughout the body while showering.
Sep 28, 2018 08:00 am ET
Covalon Announces Issuance of Stock Options
Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV:COV.V)(OTCQX:CVALF), an advanced medical technologies company,
today announced the issuance of an aggregate of 155,000 stock options to
directors, officers and staff of the Company. The stock options will
vest over three years and will be exercisable for a period of five years
at an exercise price of $8.50 per stock option.
Sep 20, 2018 12:39 pm ET
Covalon to Host Conference Call to Discuss Definitive Agreement to Acquire AquaGuard
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, has scheduled a
conference call for Friday September 21st 2018 at 9:00am EST.
Sep 20, 2018 07:00 am ET
Covalon Announces Definitive Agreement to Acquire AquaGuard and its Specialized Salesforce Capable of Selling Covalon’s Products Throughout the United States
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV.V;
OTCQX: CVALF), an advanced medical technologies company, today announces
that it has entered into a definitive agreement to acquire AquaGuard,
the Seattle, Washington-based division of medical technologies company
Cenorin, LLC. AquaGuard’s specialized products provide patients with
crucial moisture protection for wound, surgical, and vascular access
sites throughout the body while showering.
Sep 14, 2018 02:56 pm ET
Covalon to Showcase IV Clear at AVA Scientific Meeting 2018
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV.V;
OTCQX: CVALF), an advanced medical technologies company, today announces
that it will be showcasing IV Clear at the 2018 Scientific Meeting for
the Association for Vascular Access (“AVA” or the “Meeting”).
Aug 28, 2018 07:32 am ET
Covalon Announces Another Milestone Quarterly Profit on Excellent Third Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, is pleased to
announce today another milestone quarterly profit of $2.2 million on
excellent third quarter financial results.
Aug 20, 2018 08:00 am ET
Covalon Announces Receipt of First Payment Under New License Agreement
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it has received $3.5 million USD under a new license agreement
(“Agreement”) with a large global medical company (“Medical Partner”).
The Agreement provides the Medical Partner with certain rights to use
Covalon’s patented antimicrobial medical coating technology with some of
its devices. The Agreement was entered into in the ordinary course of
business of Covalon and is subject to confidentiality provi
Aug 09, 2018 05:00 pm ET
Covalon Announces Major Banking Milestone
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that the Company has entered into a new acquisition and operating
banking credit facility with HSBC Bank Canada (“HSBC”) that provides the
Company with up to $17 million of credit. In support of Covalon, Export
Development Canada (“EDC”) has partnered with HSBC to provide partial
guarantees under the banking facility.
Aug 07, 2018 11:28 am ET
Covalon Unaware of Any Material Change
At the request of the Investment Industry Regulatory Organization of
Canada (“IIROC”), Covalon Technologies Ltd. (“Covalon” or the “Company”)
wishes to confirm that the Company’s management is unaware of any
material change in the Company’s operations that would account for the
recent increase in market activity. Management of the Company does not
believe, based on its communications with the Company’s partner in Saudi
Arabia, that the reported dispute between the Government of Canada and
the Government of Saudi Arabia will have a negative impac
Jul 26, 2018 08:00 am ET
Covalon Announces Retirement of Member of Board of Directors
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announces
that Martin Bernholtz has retired as a member of the Board of Directors
of the Company, effective at the end of this month, on July 31st
2018.
Jun 12, 2018 09:00 am ET
Covalon Technologies Ltd. to Exhibit at the Largest Annual Infection Prevention and Control Conference in the World
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it will exhibit at the APIC 2018 Conference in Minneapolis,
Minnesota, June 13th to 15th.
May 28, 2018 06:18 pm ET
Covalon Announces Major Corporate Initiatives and Second Quarter Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
some major corporate initiatives and second quarter results.
May 28, 2018 08:00 am ET
Covalon to Host Conference Call to Discuss Release of Q2 Results and Initiatives
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF) an advanced medical technologies company, has scheduled a
conference call for Tuesday May 29th 2018 at 9:00 am ET.
May 22, 2018 08:00 am ET
Covalon Provides Further Information Regarding Estimated $100 Million Competitive Contract Awards
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, is pleased to
provide further information on the previously-announced series of
competitive contracts in the Middle East won by the Company with an
estimated sales value of $100 million over a three-year period.
May 07, 2018 08:00 am ET
Covalon Announces Major Sales Breakthrough – Wins Contracts with an Estimated Value of $100 Million Over a Three-Year Period
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, has been
informed that it has won a series of competitive contracts in the Middle
East with an estimated sales value of $100 million over a three-year
period.
Apr 30, 2018 10:36 am ET
Covalon to Showcase MediClear™ PreOp at AATS 2018 Annual Meeting
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it will be showcasing its perioperative suite of innovative
products, including MediClear™ PreOp, at the American Association for
Thoracic Surgery (“AATS”) Annual Meeting.
Apr 26, 2018 10:15 am ET
New Clinical Data for Covalon’s ColActive® Line of Patented Advanced Wound Care Products to be Presented at SAWC Spring
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced that two clinical
case studies demonstrating the clinical effectiveness of ColActive®
Plus and ColActive® Transfer biological matrix products will
be presented at the 2018 Symposium on Advanced Wound Care Spring (“SAWC
Spring”) in Charlotte, North Carolina. In addition to the posters,
Covalon will also be showcasing its full line of advanced wound care
dressings in the symposium’s exhibition hall dur
Apr 18, 2018 12:17 pm ET
Covalon Unaware of Any Material Change
At the request of the Investment Industry Regulatory Organization of
Canada (“IIROC”), Covalon Technologies Ltd. (the "Company" or "Covalon")
(TSXV: COV; OTCQX: CVALF), wishes to confirm that the Company’s
management is unaware of any material change in the Company’s operations
that would account for the recent increase in market activity.
Mar 26, 2018 09:20 am ET
Covalon to Feature MediClear™ PreOp at AORN Surgical Conference and Expo 2018
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it will be featuring its perioperative suite of innovative products
including MediClear™ PreOp at the Association of
periOperative Registered Nurse’s (AORN) Surgical Conference and Expo,
the largest international gathering of perioperative registered nurses
worldwide.
Mar 09, 2018 09:37 am ET
Covalon Announces Voting Results from 2018 Annual Meeting of Shareholders
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced the results of
the matters voted upon at the Company’s 2018 Annual Meeting of
Shareholders held March 8th 2018.
Mar 05, 2018 08:00 am ET
Covalon’s MediClear™ PreOp Receives Frost & Sullivan’s 2018 North American Surgical Site Infection Prevention New Product Innovation Award
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, announced today
its MediClear™ PreOp has received Frost & Sullivan’s 2018 North American
Surgical Site Infection Prevention New Product Innovation Award.
MediClear PreOp is the market’s only antimicrobial self-adherent
silicone film drape for pre-operative skin that provides continuous
antimicrobial activity to reduce the risk of bacterial contamination of
a patient’s skin prior to surgery.
Mar 01, 2018 08:00 am ET
Covalon Annual Shareholders’ Meeting to be Held Thursday March 8th 2018 at 3:30pm EST
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), announced a reminder that the Company’s Annual and
Special Shareholders’ Meeting will be held at the offices of Stikeman
Elliott LLP, 53rd floor, Commerce Court West, 199 Bay Street,
Toronto, Ontario, on Thursday March 8th 2018 at 3:30pm EST.
Feb 20, 2018 10:18 am ET
Covalon Announces its Participation in Medical Japan 2018
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that it will be participating in the Ontario Government’s Life Sciences
Trade Mission to Japan, which will include exhibiting at the Ontario
Pavilion of Medical Japan 2018 at the International Exhibition Center
(INTEX) in Osaka, Japan from February 21st to 23rd.
Feb 12, 2018 07:00 am ET
Covalon Announces Strong First Quarter Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, announced today
its first quarter financial results.
Feb 09, 2018 08:00 am ET
Covalon Announces Conference Call to Discuss Q1 Financial Results
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, has scheduled a conference call
to be held Tuesday February 13th 2018 at 9:00 a.m. EST,
to discuss the financial results of the first quarter ended December 31st
2017. The Company intends to release its Q1 financial results on Monday
February 12th 2018.
Feb 05, 2018 10:59 am ET
Covalon to Showcase Centaur™ Low Particulate, Lubricious Coating at MD&M West
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, today announced that it will be
featuring its commercially available platform technologies, including
the recently launched Centaur™ coating as first-time exhibitors at North
America’s largest annual MedTech event. MD&M West will take place at the
Anaheim Convention Center, from February 6-8, 2018.
Jan 24, 2018 06:08 pm ET
Covalon Announces Issuance of Stock Options
Further to its press release dated October 27, 2017, Covalon
Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX:
CVALF), an advanced medical technologies company, today announced the
second tranche issuance of a further 60,000 stock options to certain
financial advisors of the Company. The stock options will vest over
three years and will be exercisable for a period of five years at an
exercise price of $6.02 per stock option.
Dec 21, 2017 08:00 am ET
Covalon Announces Issuance of Stock Options
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), today announced the issuance of an aggregate of 187,500
stock options to employees, directors and consultants of the Company.
The stock options will vest over three years and will be exercisable for
a period of five years at an exercise price of $4.65 per stock option.
Dec 18, 2017 07:00 am ET
Covalon Announces Record Positive Results for Fiscal 2017
Mr. Brian Pedlar, President and CEO of Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), is delighted to
announce that Covalon has achieved the best financial results in its
history for the fiscal 2017 year-end.
Nov 14, 2017 08:00 am ET
US Major General Gale S. Pollock (Ret.) Joins Covalon’s Board of Directors
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, is extremely
pleased to announce that Major General (Ret.) Gale S. Pollock, CRNA,
FACHE, FAAN, has agreed to join Covalon’s Board of Directors.
Oct 27, 2017 07:00 am ET
Covalon Announces Issuance of Stock Options
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
the issuance of 60,000 stock options to financial advisors of the
Company. The stock options will vest over three years and will be
exercisable for a period of five years at an exercise price of $3.80 per
stock option. During January 2018, the company will issue a second
tranche of options to the financial advisors, at the future market
price, which will vest over a three year period and will be exercisable
Oct 05, 2017 08:30 am ET
Covalon to Feature its Advanced Wound Management and Infection Prevention Lines at Limb Salvage and Woundcare Symposium
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an
advanced medical technologies company, announced today that it will be
showcasing its full portfolio of Advanced Wound Management and Infection
Prevention products at the Limb Salvage and Woundcare Symposium in
Cleveland, Ohio on October 6th and 7th, 2017.
Sep 18, 2017 08:00 am ET
OTC Markets Group Welcomes Covalon Technologies to OTCQX
NEW YORK, Sept. 18, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Covalon Technologies Ltd. (TSX-V: COV; OTCQX: CVALF), a researcher, developer, manufacturer, and marketer of patent protected medical products, has qualified to trade on the OTCQX® Best Market. Covalon Technologies upgraded to OTCQX from the Pink® market.
Apr 01, 2016 11:17 am ET
Covalon to Present SurgiClear™ at AORN Surgical Conference and Expo
MISSISSAUGA, ON, April 1, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring SurgiClear™ at the Association of periOperative Registered Nurse's (AORN) Surgical Conference and Expo, the largest international gathering of perioperative registered nurses worldwide.
Apr 01, 2016 11:17 am ET
Covalon to Present SurgiClear™ at AORN Surgical Conference and Expo
MISSISSAUGA, ON, April 1, 2016 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring SurgiClear™ at the Association of periOperative Registered Nurse's (AORN) Surgical Conference and Expo, the largest international gathering of perioperative registered nurses worldwide.
Mar 07, 2016 08:00 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, March 7, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the issuance of an aggregate of 192,500 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $1.13 per stock option.
Mar 07, 2016 08:00 am ET
Covalon Announces Issuance of Stock Options
MISSISSAUGA, ON, March 7, 2016 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the issuance of an aggregate of 192,500 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $1.13 per stock option.
Mar 01, 2016 08:00 am ET
Covalon First Quarter, 2016 Earnings Conference Call
MISSISSAUGA, ON, March 1, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to discuss its Q1, fiscal 2016 financial results.
Mar 01, 2016 08:00 am ET
Covalon First Quarter, 2016 Earnings Conference Call
MISSISSAUGA, ON, March 1, 2016 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has scheduled a conference call to discuss its Q1, fiscal 2016 financial results.
Feb 29, 2016 08:00 am ET
Covalon Announces Strong First Quarter Financial Results
MISSISSAUGA, ON, Feb. 29, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2015.
Feb 29, 2016 08:00 am ET
Covalon Announces Strong First Quarter Financial Results
MISSISSAUGA, ON, Feb. 29, 2016 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2015.
Feb 09, 2016 08:00 am ET
Covalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan
MISSISSAUGA, ON, Feb. 9, 2016 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has announced a licensing agreement with the University of Michigan's Center for Integrative Research in Critical Care ("MCIRCC"), whereby Covalon has licensed intellectual property from MCIRCC that, when commercialized, could prevent or reduce the occurrence of Ventilator-Associated Pneumonia ("VAP"), a potentially devastating hospital acquired infection, and the most common nosocomial infection in critically ill patients.1
Feb 09, 2016 08:00 am ET
Covalon Licenses Intellectual Property to Prevent Ventilator-Associated Pneumonia from the University of Michigan
MISSISSAUGA, ON, Feb. 9, 2016 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, has announced a licensing agreement with the University of Michigan's Center for Integrative Research in Critical Care ("MCIRCC"), whereby Covalon has licensed intellectual property from MCIRCC that, when commercialized, could prevent or reduce the occurrence of Ventilator-Associated Pneumonia ("VAP"), a potentially devastating hospital acquired infection, and the most common nosocomial infection in critically ill patients.1
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
